NDA 219083 is the FDA application for MYQORZO (aficamten). The FDA's Orange Book lists the applicant of record as CYTOKINETICS INC and the first approval on it as Dec 19, 2025. Code names used in development: CK-274, CK-3773274. Owner today: Cytokinetics, Incorporated (Nasdaq: CYTK).
Page updated Nov 19, 2026. FDA records: Drugs@FDA NDA 219083 · Orange Book NDA 219083
| Brand name (FDA) | MYQORZO Orange Book trade name: MYQORZO |
|---|---|
| Active ingredient (FDA) | AFICAMTEN |
| Code name | CK-274 Source: Cytokinetics 10-K, Feb 25, 2022 “aficamten (also known as CK-274)” |
| Code name | CK-3773274 Source: Cytokinetics 10-K, Feb 25, 2022 “aficamten (also known asCK-3773274 or CK-274), a novel cardiac myosin inhibitor” |
| FDA applicant of record | CYTOKINETICS INC FDA Orange Book data files as of Nov 13, 2026 |
|---|---|
| Owner today | Cytokinetics, Incorporated (CYTK) Source: Cytokinetics press release, Dec 19, 2025 “Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug Administration (FDA) has approved” |
| No. | Trade name | Form; route | Strength | Approved |
|---|---|---|---|---|
| 001 | MYQORZO | TABLET;ORAL | 5MG | Dec 19, 2025 |
| 002 | MYQORZO | TABLET;ORAL | 10MG | Dec 19, 2025 |
| 003 | MYQORZO | TABLET;ORAL | 15MG | Dec 19, 2025 |
| 004 | MYQORZO | TABLET;ORAL | 20MG | Dec 19, 2025 |
Drug page: /drug/myqorzo · /drug/aficamten
Orange Book data: FDA Orange Book data files, as of Nov 13, 2026. Approval dates are the FDA's dates for each product; a later supplement (a new use) does not change them.